GET DAILY SIGNALSPepGen (PEPG) Shares Flat Near +0.4% as FREEDOM2 Data Readout Nears
Key Takeaways
- PepGen is a clinical-stage biotechnology company developing oligonucleotide therapies for neuromuscular diseases, led by PGN-EDODM1 for myotonic dystrophy type 1 (DM1).
- Over the past 30 days, PEPG shares have been roughly flat (near +0.4%), though intra-period volatility took the stock to a low around $2.21 in early October before a recovery toward $2.60.
- The dominant near-term catalyst is the Phase 2 FREEDOM2 trial, with 10 mg/kg cohort data expected in November 2026.
- PepGen reported $117.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, funding operations into the fourth quarter of 2027.
- A partial clinical hold on the FREEDOM2 study remains a key regulatory overhang as the company works to address FDA questions.
- As a pre-revenue biotech, PEPG shares are highly sensitive to clinical data readouts and regulatory developments.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore these dedicated pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are tracking stocks like PEPG.
Recent Price Action in PEPG
PEPG shares have traded in a wide, volatile range over the past month, ending near where they began. After closing around $2.59 in late September, the stock slipped to a low near $2.21 in early October before recovering to roughly $2.60. That leaves the 30-day move essentially flat, near +0.4%, even as the path between those two points featured sharp swings typical of a clinical-stage biotech awaiting a major data readout.
The broader context reflects a stock that remains well below its 52-week high. As a pre-commercial company with no product revenue, PepGen's share price is driven primarily by clinical progress, regulatory updates, and cash-runway visibility rather than earnings or sales multiples. Investor sentiment continues to hinge on the PGN-EDODM1 program and the approaching FREEDOM2 data. I also checked this using Tickeron’s AI Trend Prediction Engine to get a sense of how the stock might respond to upcoming catalysts.
PepGen Business Overview and Competitive Position
PepGen is a clinical-stage biotechnology company advancing next-generation oligonucleotide therapeutics for severe neuromuscular and neurological diseases. Its core technology is the Enhanced Delivery Oligonucleotide (EDO) platform, which leverages cell-penetrating peptides to improve tissue penetration, cellular uptake, and nuclear delivery of conjugated oligonucleotide drugs — an approach designed to overcome a longstanding delivery barrier in the field.
The company's lead candidate, PGN-EDODM1, targets myotonic dystrophy type 1 (DM1), a progressive, life-shortening genetic disorder. The therapy is designed to restore normal splicing function of MBNL1 by binding to the pathogenic CUG repeat expansion in DMPK transcripts. The U.S. Food and Drug Administration has granted PGN-EDODM1 Orphan Drug and Fast Track designations, and the European Medicines Agency has granted Orphan Designation. PepGen's pipeline also includes PGN-EDO51 and other exon-skipping candidates for Duchenne muscular dystrophy (DMD), positioning the company across two high-unmet-need neuromuscular indications.
Recent Developments Driving PEPG
The most significant recent updates center on the FREEDOM2 Phase 2 multiple ascending dose trial of PGN-EDODM1. In its second-quarter 2026 results, PepGen confirmed that the 10 mg/kg cohort was fully enrolled, with seven of eight participants having completed dosing, and that data from that cohort is expected in November 2026. An independent Data and Safety Monitoring Board (DSMB) recommended advancing the trial into the third and highest dose cohort at 12.5 mg/kg and approved dose escalation in the open-label extension study from 5 mg/kg to 10 mg/kg.
Earlier in the year, the company reported topline results from the 5 mg/kg cohort of FREEDOM2 that demonstrated a favorable tolerability profile and encouraging efficacy trends. PepGen also presented late-breaking data from the PGN-EDODM1 program at the 15th International Myotonic Dystrophy Consortium in May 2026.
A partial clinical hold on the FREEDOM2 study remains unresolved. The FDA's questions relate to previously submitted preclinical pharmacology and toxicology studies, and PepGen has said the hold has not impacted the timing of the ongoing trial. On the balance sheet, the company ended the second quarter of 2026 with $117.2 million in cash, cash equivalents, and marketable securities.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary catalyst for PepGen is the November 2026 data readout from the 10 mg/kg cohort of FREEDOM2, which will test whether repeat dosing sustains the splicing correction observed in the earlier Phase 1 FREEDOM study. An update from the open-label extension study is expected by early January, and results from the 12.5 mg/kg cohort are anticipated in the first half of 2027. Pending those results, PepGen plans to engage regulators in an end-of-Phase-2 meeting to outline a potential registrational path.
Investors should also monitor the resolution of the partial clinical hold, progress in the DMD-focused pipeline, and the company's cash runway, which management has guided into the fourth quarter of 2027. As with any clinical-stage biotech, binary data events and regulatory decisions carry meaningful risk and can drive substantial share-price volatility. From what I see, this remains a classic case where clinical milestones will likely dictate near-term moves.
AI Tools Supporting My Biotech Analysis
I find Tickeron’s AI Trading Bots particularly useful when evaluating names like PEPG that are driven by binary events. The platform lets me review a range of automated strategies and see how they have performed across similar clinical-stage stocks. It helps me cross-check my own thesis without replacing the fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PEPG's RSI Oscillator recovers from oversold territory
The RSI Oscillator for PEPG moved out of oversold territory on October 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 20 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PEPG as a result. In 76 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PEPG just turned positive on October 13, 2026. Looking at past instances where PEPG's MACD turned positive, the stock continued to rise in 35 of 39 cases over the following month. The odds of a continued upward trend are 90%.
Following a +10.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where PEPG advanced for three days, in 198 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 49 cases where PEPG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
PEPG moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PEPG crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PEPG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PEPG broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PEPG entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.506) is normal, around the industry mean (2.974). P/E Ratio (-2.600) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PEPG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PEPG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement